摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,3-二甲基-四氢-吡喃-2-酮 | 4830-05-1

中文名称
3,3-二甲基-四氢-吡喃-2-酮
中文别名
——
英文名称
3,3-Dimethyltetrahydro-2H-pyran-2-one
英文别名
3,3-dimethyltetrahydropyran-2-one;tetrahydro-3,3-dimethyl-2H-pyran-2-one;3,3-Dimethyl-tetrahydro-pyran-2-one;3,3-dimethyloxan-2-one
3,3-二甲基-四氢-吡喃-2-酮化学式
CAS
4830-05-1
化学式
C7H12O2
mdl
MFCD07369942
分子量
128.171
InChiKey
CJNWCYZELLHABH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    90 °C(Press: 8 Torr)
  • 密度:
    0.967±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2932999099
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:3114c7dd2fc9d021b4842090d04ef8cd
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] PYRAZOLYL PYRROLINONES AND THEIR USE AS HERBICIDES
    [FR] PYRAZOLYLE PYRROLINONES ET LEUR UTILISATION EN TANT QU'HERBICIDES
    摘要:
    该发明涉及式(I)的吡咯酮化合物,其中X、Ra、Rb、Rc、R1、R2和R3如规范中定义。此外,本发明涉及制备式(I)化合物的过程和中间体,包括这些化合物的除草剂组合物,以及使用这些化合物控制植物生长的方法。
    公开号:
    WO2015018434A1
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 在 乙醇sodium 作用下, 生成 3,3-二甲基-四氢-吡喃-2-酮
    参考文献:
    名称:
    Blanc, Bulletin de la Societe Chimique de France, 1905, vol. <3> 33, p. 898
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Salt suitable for an acid generator and a chemically amplified resist composition containing the same
    申请人:Harada Yukako
    公开号:US20070078269A1
    公开(公告)日:2007-04-05
    The present invention provides a salt of the formula (I): wherein ring Y represents monocyclic or polycyclic hydrocarbon group having 3 to 30 carbon atoms, in which one —CH 2 — group is substituted with —COO— group, and at least one hydrogen atom in the monocyclic or polycyclic hydrocarbon group may optionally be substituted with alkyl group having 1 to 6 carbon atom, alkoxy group having 1 to 6 carbon atom, perfluoroalkyl group having 1 to 4 carbon atoms, hydroxyalkyl group having 1 to 6 carbon atoms, hydroxyl group or cyano group; Q 1 and Q 2 each independently represent fluorine atom or perfluoroalkyl group having 1 to 6 carbon atoms; A + represents organic counter ion; and n shows an integer of 0 to 12. The present invention also provides a chemically amplified resist composition comprising the salt of the formula (I).
    本发明提供了一种具有公式(I)的盐: 其中环Y代表具有3至30个碳原子的单环或多元环烃基团,其中一个—CH2—基团被—COO—基团取代,并且单环或多元环烃基团中的至少一个氢原子可以可选地被具有1至6个碳原子的烷基取代,具有1至6个碳原子的烷氧基,具有1至4个碳原子的全氟烷基,具有1至6个碳原子的羟基烷基,羟基或腈基;Q1和Q2各自独立地代表氟原子或具有1至6个碳原子的全氟烷基;A+代表有机反离子;n表示0至12的整数。 本发明还提供了一种含有公式(I)盐的化学放大抗蚀剂组合物。
  • Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor
    作者:He Tian、Wei Liu、Zhixing Zhou、Qian Shang、Yuqiang Liu、Yafei Xie、Changying Liu、Weiren Xu、Lida Tang、Jianwu Wang、Guilong Zhao
    DOI:10.3390/molecules21111543
    日期:——
    In order to systematically explore and understand the structure–activity relationship (SAR) of a lesinurad-based hit (1c) derived from the replacement of the S atom in lesinurad with CH2, 18 compounds (1a–1r) were designed, synthesized and subjected to in vitro URAT1 inhibitory assay. The SAR exploration led to the discovery of a highly potent flexible URAT1 inhibitor, 1q, which was 31-fold more potent than parent lesinurad (IC50 = 0.23 μM against human URAT1 for 1q vs 7.18 μM for lesinurad). The present study discovered a flexible molecular scaffold, as represented by 1q, which might serve as a promising prototype scaffold for further development of potent URAT1 inhibitors, and also demonstrated that the S atom in lesinurad was not indispensable for its URAT1 inhibitory activity.
    为了系统地探索和理解基于lesinurad的命中化合物(1c)的结构-活性关系(SAR),该化合物是通过将lesinurad中的S原子替换为CH2得到的,设计并合成了18个化合物(1a–1r),并对其进行了体外URAT1抑制活性测试。SAR探索发现了一个高效的柔性URAT1抑制剂1q,其活性比母体lesinurad高31倍(对于人URAT1的IC50值,1q为0.23 μM,而lesinurad为7.18 μM)。本研究发现了一种柔性分子骨架,如1q所示,这可能作为进一步开发高效URAT1抑制剂的有前景的原型骨架,并且表明lesinurad中的S原子对其URAT1抑制活性并非必需。
  • [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
    申请人:ABBVIE INC
    公开号:WO2018068283A1
    公开(公告)日:2018-04-19
    Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    本文提供了式(I)的化合物,其中R 1、Y、L 1、G 1、X 1、X 2、L 2、R 2、R 3和R 4具有规范中定义的任何值,以及其药学上可接受的盐,这些化合物在治疗疾病和病况中是有用的,包括炎症性疾病、癌症和艾滋病。还提供了包含式(I)化合物的药物组合物。
  • [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY<br/>[FR] DÉRIVÉS DE N-PYRIDYL ACÉTAMIDE UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION WNT
    申请人:REDX PHARMA PLC
    公开号:WO2016055786A1
    公开(公告)日:2016-04-14
    This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
    这项发明涉及化合物。更具体地,该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说,该发明考虑了Porcupine(Porcn)的抑制剂。此外,该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此,该发明的化合物可用于治疗由Wnt信号通路介导的疾病,例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病;或增强抗癌治疗的有效性。
  • [EN] 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS<br/>[FR] 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES EN TANT QU'INHIBITEURS DE JAK2
    申请人:AJAX THERAPEUTICS INC
    公开号:WO2021226261A1
    公开(公告)日:2021-11-11
    The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.
    本公开提供了6-杂芳氧基苯并咪唑和氮杂苯并咪唑化合物及其组合物,用于抑制JAK2。
查看更多